A Phase 4 interventional study of liraglutide and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 106 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 18 that started in 2013, is one of 48 in phase 4, and was the 79th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 407 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 130th largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 75 in phase 4, and was the 352nd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 407 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide · Drug: placebo
Drug: sitagliptin · Drug: placebo
Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
Sitagliptin placebo tablets once-daily
Sitagliptin placebo tablets once-daily
Change in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c was analysed after 26 weeks of treatment. Analysis population set: full analysis set (FAS); all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using mixed model for repeated measurements (MMRM).
Time frame: From baseline to week 26
Change in Body Weight
Change from baseline in body weight was analysed after 26 weeks of treatment. Analysis population set: FAS: all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using MMRM.
Time frame: From baseline to week 26
Change in Fasting Plasma Glucose
Change from baseline in fasting plasma glucose was analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
Time frame: From baseline to week 26
Change in Fasting Blood Lipids
Ratio to baseline in fasting blood lipids (total cholesterol, low density lipoprotein \[LDL\], very low density lipoprotein \[VLDL\], high density lipoprotein \[HDL\], triglycerides, and free fatty acids) were analysed after 26 weeks treatment. Missing values were imputed using MMRM. Here we are presenting ratio to baseline data.
Time frame: From baseline to week 26
Change in Systolic Blood Pressure and Diastolic Blood Pressure
Change from baseline in systolic and diastolic blood pressure were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
Time frame: From baseline to week 26
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) (American Diabetes Association Target) (y/n)
Number of subjects who achieve HbA1c \<7.0% were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
Time frame: After 26 weeks of treatment
Number of Treatment Emergent Adverse Events (TEAEs)
A treatment emergent adverse event (TEAE) was defined as an event that had an onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. The number of TEAEs was recorded during 26 weeks of treatment plus one week follow-up period.
Time frame: During 26 weeks of treatment plus one week follow-up period.
The trial was conducted at 86 sites in 6 countries: Canada (14); Hungary (8); India (7); Israel (8); Spain (6); and United States (43).
| Milestone | Liraglutide | Sitagliptin |
|---|---|---|
| Started | 203 | 204 |
| Exposed | 202 | 204 |
| Completed | 187 | 191 |
| Not completed | 16 | 13 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 9 | 7 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Unclassified | 4 | 3 |
Change from baseline in HbA1c was analysed after 26 weeks of treatment. Analysis population set: full analysis set (FAS); all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using mixed model for repeated measurements (MMRM).
| percentage of glycosylated haemoglobin | Liraglutide | Sitagliptin |
|---|---|---|
| Change in HbA1c (Glycosylated Haemoglobin) | -1.146 ± 0.9748 | -0.529 ± 1.0148 |
Change from baseline in body weight was analysed after 26 weeks of treatment. Analysis population set: FAS: all randomised subjects receiving at least one dose of any of the trial products. Missing values were imputed using MMRM.
| kg | Liraglutide | Sitagliptin |
|---|---|---|
| Change in Body Weight | -3.32 ± 3.135 | -1.80 ± 2.974 |
Change from baseline in fasting plasma glucose was analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
| nmol/L | Liraglutide | Sitagliptin |
|---|---|---|
| Change in Fasting Plasma Glucose | -1.967 ± 2.3585 | -0.588 ± 2.1363 |
Ratio to baseline in fasting blood lipids (total cholesterol, low density lipoprotein \[LDL\], very low density lipoprotein \[VLDL\], high density lipoprotein \[HDL\], triglycerides, and free fatty acids) were analysed after 26 weeks treatment. Missing values were imputed using MMRM. Here we are presenting ratio to baseline data.
| ratio | Liraglutide | Sitagliptin |
|---|---|---|
| Total cholesterol | 1.011 ± 0.1906 | 1.045 ± 0.2323 |
| LDL cholesterol | 1.049 ± 0.3899 | 1.121 ± 0.4661 |
| VLDL cholesterol | 1.062 ± 0.4236 | 1.075 ± 0.4625 |
| HDL cholesterol | 1.004 ± 0.1528 | 0.997 ± 0.1548 |
| Triglycerides | 1.089 ± 0.4975 | 1.099 ± 0.4889 |
| Free Fatty acids | 1.086 ± 0.774 | 1.104 ± 0.5839 |
Change from baseline in systolic and diastolic blood pressure were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
| mmHg | Liraglutide | Sitagliptin |
|---|---|---|
| Systolic Blood Pressure | -3.6 ± 11.596 | -2.57 ± 11.593 |
| Diastolic Blood Pressure | -0.23 ± 7.085 | -0.81 ± 7.193 |
Number of subjects who achieve HbA1c \<7.0% were analysed after 26 weeks of treatment. Missing values were imputed using MMRM.
| percentage (%) | Liraglutide | Sitagliptin |
|---|---|---|
| Yes | 50.6 | 26.9 |
| No | 49.4 | 73.1 |
A treatment emergent adverse event (TEAE) was defined as an event that had an onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. The number of TEAEs was recorded during 26 weeks of treatment plus one week follow-up period.
| number of events | Liraglutide | Sitagliptin |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 455 | 318 |
Collected over 27 weeks (26 weeks of treatment period + 1 week of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide | — | 6/202 (3%) | 96/202 (47.5%) |
| Sitagliptin | — | 7/204 (3.4%) | 61/204 (29.9%) |
| Event | Liraglutide | Sitagliptin |
|---|---|---|
| FallInjury, poisoning and procedural complications | 2/202 | 0/204 |
| Acute coronary syndromeCardiac disorders | 1/202 | 0/204 |
| Cardiac failure congestiveCardiac disorders | 1/202 | 0/204 |
| Prinzmetal anginaCardiac disorders | 1/202 | 0/204 |
| PneumoniaInfections and infestations | 1/202 | 1/204 |
| DepressionPsychiatric disorders | 1/202 | 0/204 |
| Joint arthroplastySurgical and medical procedures | 1/202 | 0/204 |
| Myocardial ischaemiaCardiac disorders | 0/202 | 1/204 |
| Non-cardiac chest painGeneral disorders | 0/202 | 1/204 |
| Pneumococcal sepsisInfections and infestations | 0/202 | 1/204 |
| Event | Liraglutide | Sitagliptin |
|---|---|---|
| NauseaGastrointestinal disorders | 44/202 | 16/204 |
| DiarrhoeaGastrointestinal disorders | 33/202 | 19/204 |
| Decreased appetiteMetabolism and nutrition disorders | 18/202 | 7/204 |
| VomitingGastrointestinal disorders | 15/202 | 10/204 |
| HeadacheNervous system disorders | 13/202 | 12/204 |
| Upper respiratory tract infectionInfections and infestations | 12/202 | 13/204 |
| NasopharyngitisInfections and infestations | 12/202 | 7/204 |
| Lipase increasedInvestigations | 11/202 | 9/204 |
Demographics and baseline characteristics of all exposed subjects are summarised in continuous variables. There were missing baseline values for fasting plasma glucose in 2 subjects in the liraglutide arm and 1 subject in the sitagliptin arm.
| Age, Continuous(years) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 56.3 ± 10.6 | 56.5 ± 9.7 | 56.4 ± 10.2 |
| Sex: Female, Male(Participants) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Female | 85 | 79 | 164 |
| Male | 117 | 125 | 242 |
| HbA1c(percentage of glycosylated haemoglobin) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 8.3 ± 0.6 | 8.2 ± 0.6 | 8.3 ± 0.6 |
| Body Weight(kg) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 88.9 ± 19.8 | 91.2 ± 19.6 | 90.1 ± 19.7 |
| Fasting Plasma Glucose(mmol/L) | Liraglutide | Sitagliptin | Total |
|---|---|---|---|
| Mean | 10.0 ± 2.7 | 9.7 ± 2.5 | 9.9 ± 2.6 |
Showing the first 100 of 106 sites across 7 countries. Choose a country and city above to see the rest.
Ran from Dec 2013 to primary completion in Jun 2015, 18 months.
Results were first posted in Jul 2016, 1 year after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 18 months is close to that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liraglutide · Sitagliptin